Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient

被引:0
|
作者
Franceschini, Gianluca [1 ]
Di Leone, Alba [1 ]
Sanchez, Alejandro Martin [1 ]
D'Archi, Sabatino [1 ]
Terribile, Daniela [1 ]
Magno, Stefano [1 ]
Scardina, Lorenzo [1 ]
Masetti, Riccardo [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, Dept Woman Child & Publ Hlth, IRCCS,Div Breast Surg, Largo Agostino Gemelli 8, I-00168 Rome, Italy
关键词
Axillary treatment; Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node biopsy; AXILLARY DISSECTION; MANAGEMENT;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Today, sentinel lymph node biopsy (SLNB) is considered the gold standard for axillary staging in early breast cancer patients with clinically negative lymph nodes (cNO). SLNB allows to determine the axillary lymph node status sparing the axillary dissection (AD) and its potential complications (seroma formation, loss of sensation, shoulder dysfunction and lymphedema) On the other hand, SLNB for nodal staging in breast cancer patients with clinically negative lymph nodes after neoadjuvant chemotherapy (ycN0) is a highly debated topic due to different reported success rates. In order to optimize oncological results, high identification rate (> 90%) and false negative rate as low as possible (< 10%) should always be obtained when performing SLNB after neoadjuvant chemotherapy. The success rates of SLNB after neoadjuvant chemotherapy (NAC) mainly depend on the clinical lymph node status pre-NAC. In patients with pre-NAC clinically negative nodes (cN0) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy should be performed because it is an accurate and safe procedure. In patients with pre-NAC clinically positive nodes (cN+) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy might be considered thanks to the high lymph nodal pathologic complete response rate; however, in this last setting, individual ability, technical skills and repetitive performance of specific tasks must always be followed to improve the identification rate and false negative rate. AD may be avoided only if sentinel lymph node is negative [ypN0(sn)J; instead, to date, patients with metastatic sentinel lymph node after neoadjuvant chemotherapy, even with only isolated tumor cells, fypN+(sn) including ypN0i+(sn) and ypN1mic(sn)J should always be treated with AD. However, NAC significantly increases the difficulties and complexity of axillary surgical management. A personalized multidisciplinary path in specialized breast centers should ensure an accurate clinical counselling and refined patient selection for SLNB post-NAC.
引用
收藏
页码:465 / 468
页数:4
相关论文
共 50 条
  • [1] Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer
    Hino, Masato
    Sano, Muneaki
    Sato, Nobuaki
    Homma, Keiichi
    SURGERY TODAY, 2008, 38 (07) : 585 - 591
  • [2] Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer
    Masato Hino
    Muneaki Sano
    Nobuaki Sato
    Keiichi Homma
    Surgery Today, 2008, 38
  • [3] Sentinel lymph node biopsy and neoadjuvant chemotherapy in breast cancer patients
    Benson, John R.
    Jatoi, Ismail
    FUTURE ONCOLOGY, 2014, 10 (04) : 577 - 586
  • [4] Sentinel Lymph Node Biopsy Before Versus After Neoadjuvant Chemotherapy for Breast Cancer
    Shimazu, Kenzo
    Noguchi, Shinzaburo
    SURGERY TODAY, 2011, 41 (03) : 311 - 316
  • [5] Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
    Julian, TB
    Patel, N
    Dusi, D
    Olson, P
    Nathan, G
    Jasnosz, K
    Isaacs, G
    Wolmark, N
    AMERICAN JOURNAL OF SURGERY, 2001, 182 (04) : 407 - 410
  • [6] Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy
    Reitsamer, R
    Peintinger, F
    Rettenbacher, L
    Prokop, E
    JOURNAL OF SURGICAL ONCOLOGY, 2003, 84 (02) : 63 - 67
  • [7] Sentinel Lymph Node Biopsy in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
    Pecha, Vaclav
    Kolarik, Dusan
    Kozevnikova, Renata
    Hovorkova, Karolina
    Hrabetova, Petruse
    Halaska, Michael
    Sottner, Oldrich
    Trnkova, Marketa
    Petruzelka, Lubos
    Kolarova, Hana
    CANCER, 2011, 117 (20) : 4606 - 4616
  • [8] Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer
    Kenzo Shimazu
    Shinzaburo Noguchi
    Surgery Today, 2011, 41 : 311 - 316
  • [9] Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer
    Hidar, Samir
    Bibi, Mohamed
    Gharbi, Olfa
    Tebra, Sameh
    Trabelsi, Amel
    Korbi, Sadok
    Bouaouina, Nouredine
    Ben Ahmed, Slim
    Khai, Hedi
    INTERNATIONAL JOURNAL OF SURGERY, 2009, 7 (03) : 272 - 275
  • [10] Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with breast cancer
    Dixon, John Michael
    BREAST CANCER MANAGEMENT, 2015, 4 (06) : 271 - 274